Scholarlink

<p>Oropharyngeal squamous cell carcinoma (OPSCC), increasingly linked to Human Papilloma Virus (HPV) in younger populations, is commonly treated with concurrent chemoradiotherapy (chemoRT). A prospective observational study evaluated swallowing outcomes in 20 histologically confirmed OPSCC patients pre- and 3 months post-chemoRT using objective tools - Fiberoptic Endoscopic Evaluation of Swallowing (FEES), Penetration-Aspiration Scale (PAS), Yale Pharyngeal Residue Severity Rating Scale (YPRS), and Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) and subjective tools − 100 mL Water Swallow Test, FOIS, and the MD Anderson Dysphagia Inventory (MDADI). FOIS and MDADI scores declined significantly post-treatment (<i>p</i> = 0.05 and <i>p</i> = 0.001) suggesting deteriorated swallowing function and quality of life. No significant changes were observed in PAS, YPRS, DIGEST, or 100 mL test. Tobacco chewing correlated with poorer FOIS scores (<i>p</i> = .022); smoking and alcohol showed no significant impact. T3 tumors caused greater MDADI decline vs. T2 (<i>p</i> = .003). Although objective swallowing remained mostly stable, chemoRT negatively impacted perceived swallowing quality. Routine post-treatment swallowing assessments and rehabilitation are recommended.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Swallowing Outcomes in Oropharyngeal Carcinoma Patients Post Radiotherapy Combined with Concurrent Chemotherapy

  • 期刊论文

  • 发表日期：

    2026年2月18日

查看全文
  • Kundana Devalla,
  • Kailesh Pujary,
  • Shama Shetty,
  • Venkata Raja Aithal,
  • Anshul Singh

摘要

Oropharyngeal squamous cell carcinoma (OPSCC), increasingly linked to Human Papilloma Virus (HPV) in younger populations, is commonly treated with concurrent chemoradiotherapy (chemoRT). A prospective observational study evaluated swallowing outcomes in 20 histologically confirmed OPSCC patients pre- and 3 months post-chemoRT using objective tools - Fiberoptic Endoscopic Evaluation of Swallowing (FEES), Penetration-Aspiration Scale (PAS), Yale Pharyngeal Residue Severity Rating Scale (YPRS), and Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) and subjective tools − 100 mL Water Swallow Test, FOIS, and the MD Anderson Dysphagia Inventory (MDADI). FOIS and MDADI scores declined significantly post-treatment (p = 0.05 and p = 0.001) suggesting deteriorated swallowing function and quality of life. No significant changes were observed in PAS, YPRS, DIGEST, or 100 mL test. Tobacco chewing correlated with poorer FOIS scores (p = .022); smoking and alcohol showed no significant impact. T3 tumors caused greater MDADI decline vs. T2 (p = .003). Although objective swallowing remained mostly stable, chemoRT negatively impacted perceived swallowing quality. Routine post-treatment swallowing assessments and rehabilitation are recommended.